Italia markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
17,07+0,50 (+3,02%)
Alla chiusura: 05:35PM CET
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

    First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity